The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema

Hereditary angioedema (HAE) manifests as intermittent, painful attacks of submucosal oedema affecting the larynx, gastrointestinal tract or limbs. Currently, acute treatment is available in Europe but not USA, and requires intravenous administration of a pooled blood product. HAE is most likely caused by dysinhibition of the contact cascade, resulting in overproduction of bradykinin. DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously. In a placebo-controlled Phase II trial in patients with HAE, DX-88 resulted in significant improvement in symptoms compared with placebo. A Phase III trial is ongoing. This review explains the pathophysiology of HAE and the mechanism by which DX-88, a non-intravenous, nonplasma-derived therapy, might improve the disease, and discusses the clinical course of HAE and available treatments. Finally, it explores the potential value and efficacy of DX-88 in treating HAE.

[1]  C. Feighery,et al.  Degradation of C1-Inhibitor by Plasmin: Implications for the Control of Inflammatory Processes , 1997, Molecular medicine.

[2]  M. Cicardi,et al.  Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. , 1997, The Journal of allergy and clinical immunology.

[3]  T. Caballero,et al.  Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. , 2006, Journal of Allergy and Clinical Immunology.

[4]  W. Lumry,et al.  Interim Results of EDEMA2, a Multicenter, Open-label, Repeat-Dosing Study of Intravenous and Subcutaneous Administration of Ecallantide (DX-88) in Hereditary Angioedema , 2006 .

[5]  R. Colman,et al.  The regulation of human factor XIIa by plasma proteinase inhibitors. , 1985, The Journal of biological chemistry.

[6]  R. Hoffman,et al.  Hematology: Basic Principles and Practice , 1995 .

[7]  M. Greaves,et al.  Angioedema: manifestations and management. , 1991, Journal of the American Academy of Dermatology.

[8]  G. Tsokos,et al.  Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. , 1986, The Journal of allergy and clinical immunology.

[9]  H. Müller-Eberhard,et al.  Generation of bradykinin during incubation of hereditary angioedema plasma , 1982 .

[10]  M. Cicardi,et al.  Bradykinin-mediated angioedema. , 2002, The New England journal of medicine.

[11]  M. Frank.  Hereditary angioedema: a half century of progress. , 2004, The Journal of allergy and clinical immunology.

[12]  M. Cicardi,et al.  How do we treat patients with hereditary angioedema. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[13]  A. Davis.  C1 inhibitor and hereditary angioneurotic edema. , 1988, Annual review of immunology.

[14]  R. Colman,et al.  Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. , 1981, Biochemistry.

[15]  A. Davis,et al.  Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. , 2002, The Journal of clinical investigation.

[16]  J. A. Grant,et al.  Hereditary angioedema: its diagnostic and management perspectives. , 1990, The American journal of medicine.

[17]  J. Lindner,et al.  Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: a review , 2003 .

[18]  R. Polk.  Anaphylactoid reactions to glycopeptide antibiotics. , 1991, The Journal of antimicrobial chemotherapy.

[19]  S. Thiel,et al.  Control of the classical and the MBL pathway of complement activation. , 2000, Molecular immunology.

[20]  M. Cicardi,et al.  Recent advances in the use of C1 inhibitor as a therapeutic agent. , 2003, Molecular immunology.

[21]  Z. Oltvai,et al.  C1 inhibitor deficiency: molecular and immunologic basis of hereditary and acquired angioedema. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[22]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[23]  W. Reimold.  [Pathogenesis of hereditary angioedema]. , 1987, Zeitschrift fur Gastroenterologie.

[24]  K. Bork,et al.  Hepatocellular adenomas in patients taking danazol for here ditary angiooedema , 1999, The Lancet.

[25]  D. Alling,et al.  Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. , 1972, The New England journal of medicine.

[26]  A. Kaplan,et al.  Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. , 1983, The Journal of allergy and clinical immunology.

[27]  R. Colman,et al.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. , 1982, The Journal of clinical investigation.

[28]  K. Bork,et al.  Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. , 1989, The Journal of allergy and clinical immunology.

[29]  K. Bork,et al.  Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema , 2005, Transfusion.

[30]  Robert B Sim,et al.  C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. , 1979, The Biochemical journal.

[31]  B. Wiman,et al.  Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s. , 2005, European journal of biochemistry.

[32]  F van der Graaf,et al.  Inactivation of kallikrein in human plasma. , 1983, The Journal of clinical investigation.

[33]  K. Kragballe,et al.  Hereditary Angioedema. , 2018, The New England journal of medicine.

[34]  William H. Yang,et al.  Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2004, The Journal of allergy and clinical immunology.

[35]  Anthony Williams,et al.  DX-88 and HAE: a developmental perspective. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[36]  M. Steer,et al.  Preoperative localization of nonpalpable breast lesions demonstrated by mammography. , 1976, The New England journal of medicine.

[37]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[38]  M. Frank,et al.  Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. , 1988, The Journal of allergy and clinical immunology.

[39]  C. Pozzilli,et al.  Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a , 1998 .

[40]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[41]  M. López-Trascasa,et al.  Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[42]  M. Cicardi,et al.  Pathogenetic and clinical aspects of C1 inhibitor deficiency. , 1998, Immunobiology.

[43]  M. Cicardi,et al.  Bradykinin and the pathophysiology of angioedema. , 2003, International immunopharmacology.

[44]  H. Bürgi,et al.  Type I hereditary angio‐oedema. Variability of clinical presentation and course within two large kindreds , 1997, Journal of internal medicine.

[45]  R. Ladner,et al.  Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. , 1996, Biochemistry.

[46]  J. Bissler,et al.  Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein. , 1995, The Journal of clinical investigation.

[47]  R. Ziccardi.  Activation of the early components of the classical complement pathway under physiologic conditions. , 1981, Journal of immunology.

[48]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[49]  F. Rosen,et al.  A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema , 1998, Transfusion.

[50]  A. Davis,et al.  Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability‐enhancing activities , 1994, Clinical and experimental immunology.

[51]  M. Burnier,et al.  Recent clinical trials with omapatrilat: New developments , 2003, Current hypertension reports.

[52]  J. Gelfand,et al.  Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. , 1979, The Journal of clinical investigation.

[53]  K. Bork,et al.  Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. , 2003, The American journal of medicine.

[54]  T. Williams.  DX-88, a novel recombinant protein inhibitor of plasma kallikrein: Safety and immunogenicity in early studies , 2005 .

[55]  K. Bork,et al.  Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. , 2003, Archives of internal medicine.

[56]  M. Frank,et al.  Complement 1 Inhibitor Is a Regulator of the Alternative Complement Pathway , 2001, The Journal of experimental medicine.

[57]  C. Hack,et al.  Modulation of Contact System Proteases by Glycosaminoglycans , 1996, The Journal of Biological Chemistry.

[58]  C. Cochrane,et al.  Detection of active kallikrein in induced blister fluids of hereditary angioedema patients , 1980, The Journal of experimental medicine.

[59]  M. Borggrefe,et al.  Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. , 2002, Seminars in thrombosis and hemostasis.

[60]  H. Longhurst.  Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? , 2005, International journal of clinical practice.

[61]  R. Colman,et al.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. , 1984, The Journal of clinical investigation.

[62]  M. Tosi.  Molecular genetics of C1 inhibitor. , 1998, Immunobiology.

[63]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[64]  M. Cicardi,et al.  Local bradykinin generation in hereditary angioedema. , 1999, The Journal of allergy and clinical immunology.

[65]  A. Kaplan,et al.  Does C-2 kinin exist? , 2005, The Journal of allergy and clinical immunology.

[66]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[67]  B. Ritchie.  Protease inhibitors in the treatment of hereditary angioedema. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[68]  J. Rouleau,et al.  Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. , 2001, American journal of physiology. Heart and circulatory physiology.

[69]  R. Ladner,et al.  Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein , 1996, Molecular Diversity.

[70]  J. Gelfand,et al.  Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. , 1980, The New England journal of medicine.

[71]  B. Zuraw.  Diagnosis and management of hereditary angioedema: an American approach. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[72]  A. Schmaier,et al.  Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator* , 2002, The Journal of Biological Chemistry.

[73]  A. Kaplan,et al.  Formation of bradykinin: a major contributor to the innate inflammatory response. , 2005, Advances in immunology.

[74]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.